REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. AMENDMENT NO. 4 TO LETTER AGREEMENTDevelopment Program Letter Agreement • November 14th, 2023 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment No. 4 (“Amendment No. 4”) to the Development Program Letter Agreement of May 16, 2017, as amended on July 13, 2018, July 30, 2019 and December 21, 2021 (as amended, the “Agreement”), is entered into and effective as of September 25, 2023 (the “Amendment No. 4 Effective Date”) by and between Arcturus Therapeutics, Inc. (“Arcturus”) and the Cystic Fibrosis Foundation (“CFF”). Capitalized terms used but not defined herein have the meanings given to them in the Agreement.
REDACTED Certain identified information, indicated by [***], has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm if publicly disclosed. Amendment number one to COLLABORATION AND LICENSE...Collaboration and License Agreement • November 14th, 2023 • Arcturus Therapeutics Holdings Inc. • Pharmaceutical preparations
This Amendment Number One to Collaboration and License Agreement (this “Amendment”) is made and entered into on August 3, 2023 (the “Amendment Effective Date”) and amends the Collaboration Agreement by and between Arcturus Therapeutics, Inc., a Delaware corporation (“Arcturus”), and Seqirus Inc., a Delaware corporation (“Seqirus”). Arcturus and Seqirus are sometimes referred to herein individually as a “Party” and together as the “Parties.” Capitalized terms used in this Amendment that are not defined herein shall have the meanings ascribed to such terms in the Collaboration Agreement.
